|Day Low/High||22.30 / 22.80|
|52 Wk Low/High||17.92 / 36.83|
Anticipated U.S. launch in mid-2017
Pacific Biosciences of California, AMAG Pharmaceuticals and Global Blood Therapeutics were among the biotech stock movers in premarket trading on Tuesday.
The most recent short interest data has been released for the 01/31/2017 settlement date, which shows a 1,238,470 share increase in total short interest for AMAG Pharmaceuticals, Inc. , to 7,338,003, an increase of 20.30% since 01/13/2017.
Anticipated new drug application (NDA) filing in early 2018
Will Also Report Second Quarter 2017 Results and Discuss Next Steps in its Development Programs
Supplemental new drug application on track for second quarter 2017 filing
Will Discuss Development of Other Programs
Grant awards in 2016 support promising research aimed at improving the health of mothers and babies
In trading on Thursday, shares of AMAG Pharmaceuticals, Inc. crossed below their 200 day moving average of $23.98, changing hands as low as $23.80 per share.